Dr. Bui is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
14911 National Ave #1
Los Gatos, CA 95032Phone+1 408-384-9284Fax+1 408-847-6196
Summary
- Dr. Lynne Bui is an Oncologist based in Los Gatos, CA, with subspecialties in Breast Cancer, Gastrointestinal Cancer, and Hematologic Oncology. She completed her fellowship and residency in Hematology and Medical Oncology, and Internal Medicine, respectively, at the UCLA David Geffen School of Medicine/UCLA Medical Center. She is an experienced practitioner with a focus on clinical research, drug development, clinical trials, and FDA and EMEA interactions. Dr. Bui has a strong publication record, publishing in a variety of medical research journals, and contributing to clinical trials for the treatment of several types of cancer. She has helped to develop multiple new drugs in the last decade to help thousands of patients worldwide, including carfilzomib, cabozantinib, abiraterone and enzalutamide.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
- David Geffen School of Medicine at UCLAClass of 1997
Certifications & Licensure
- CA State Medical License 1998 - 2026
Clinical Trials
- Study of XL999 in Patients With Previously Treated Ovarian Cancer Start of enrollment: 2006 Jan 01
- Study of XL999 in Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Dec 01
- Study of XL999 in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2005 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 43 citationsKey considerations in the preclinical development of biosimilars.Lynne A. Bui, Susan Hurst, Gregory L. Finch, Beverly Ingram, Ira Jacobs
Drug Discovery Today. 2015-05-01 - 1 citationsThe preclinical development of biosimilars: introduction.Lynne A. Bui
Drug Discovery Today. 2015-05-01 - 35 citationsPhase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.Srdan Verstovsek, Constantine S. Tam, Martha Wadleigh, Lubomir Sokol, Catherine C. Smith
Leukemia Research. 2014-03-01
Press Mentions
- Leaps by Bayer and Khloris Join Forces to Develop Induced Pluripotent Stem Cells (iPSCs) as Breakthrough Anti-Cancer VaccinesApril 2nd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: